After normalizing to reference samples, we identified consistent alterations to the secretome of tumor cells treated with TGFβ1, with highly significant increases in the expression of CCL3, 5, 6, 11, 12, 17, 19, 20, 21, and 22. This evidence concerns the gene CCL3 and neoplasm.